Progenesis

What Progenesis does

Progenesis is a private genetic testing services company founded in 2015 and headquartered in La Jolla, California, that specializes in preimplantation genetic testing (PGT) for the in-vitro fertilization (IVF) market. The company operates two laboratories — Progenesis USA Lab in La Jolla and Progenesis Brasil Lab in São Paulo (inaugurated in 2023) — and serves IVF clinics, reproductive endocrinologists, embryologists, and IVF patients across the United States, Latin America, India, Africa, and Europe through a network of regional and global sales representatives.

The company's core product portfolio is the Previda® family of tests built on validated Next Generation Sequencing (NGS) technology with proprietary algorithms. Previda® (PGT-A) screens embryos for chromosomal aneuploidies; Previda®-DX (PGT-M) detects single-gene disorders and known structural variants; Previda-SR+ (PGT-SR+) performs high-resolution breakpoint mapping for chromosomal rearrangements including translocations and inversions; and Previda®-Plus handles triploidy, haploidy, and embryo parentage testing. Test-Nima extends the platform to whole-genome sequencing. The Revela® HIPAA-compliant portal serves as the operational backbone, providing case management, consent form tracking, encrypted result delivery, and performance monitoring for clinics and patients, while Progenesis Academy and the annual GENES Conference deliver educational programming to the reproductive medicine community.

Progenesis generates revenue by selling PGT services to IVF clinics through a B2B enterprise field sales motion, with tests ordered by physicians and coordinated through clinics. The company facilitates patient access via five third-party financing partnerships (Future Family, LendingClub, Progyny, Win Fertility, Gaia Family). Pricing is not publicly disclosed. The company holds CAP accreditation, CLIA certification, and a New York State CLEP license, and is led by founder and CEO Nabil Arrach (Ph.D., MBA) alongside a management team that includes dedicated directors for bioinformatics (India), LATAM business development, sales and marketing, medical affairs, quality assurance, and operations.

Name

Progenesis

Legal name

Progenesis, Inc.

Website

https://progenesis.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Progenesis is a private genetic testing company founded in 2015 that provides preimplantation genetic testing (PGT-A, PGT-M, PGT-SR+) using NGS technology for IVF clinics, reproductive endocrinologists, embryologists, and patients across the US, Latin America, India, and Africa.

Ownership category

akta.pro rank

Headquarters

HQ city

La Jolla

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Genetic Testing Services: Progenesis provides specialized genetic testing services to IVF clinics, including PGT-A, PGT-SR, and PGT-M testing. Testing is initiated by physicians and coordinated through IVF clinics. Results are reported to the IVF care team for use in their evaluation process alongside other clinical and laboratory findings.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Progenesis provides specialized preimplantation genetic testing (PGT) services for IVF clinics and patients, including aneuploidy screening (PGT-A), single-gene disorder testing (PGT-M), and structural rearrangement analysis (PGT-SR/SR+). Testing is initiated by physicians, processed in Progenesis's CLIA-certified and CAP-accredited laboratories using next generation sequencing (NGS) technology, and coordinated through the Revela HIPAA-compliant online portal for case management and secure reporting.

Product overview

Progenesis provides specialized genetic testing services for IVF, organized as a unified product portfolio anchored by the Previda® family of preimplantation genetic testing (PGT) products and the Revela® online portal. The Previda® products include Previda® (PGT-A for aneuploidy screening), Previda®-DX (PGT-M for single-gene disorders), Previda-SR+ (PGT-SR/SR+ for chromosomal rearrangements), and Previda®-Plus (triploidy and parentage testing). Clinics use the Revela® portal for case management, secure reporting, consent management, and results delivery. Progenesis Academy and the GENES Conference provide educational and community resources for the reproductive medicine community.

Differentiator

Problem solved

Functional benefit

Brands

• Previda: Preimplantation genetic testing for aneuploidy (PGT-A) - embryo screening test for chromosome copy number evaluation
• Previda-DX
• Previda-SR+
• Revela
• Progenesis Academy
• GENES Conference

Products and services

• Previda® (PGT-A) Laboratory test performed on embryos during IVF cycles to evaluate chromosome copy number, screening for aneuploidies such as missing or extra chromosomes (monosomies or trisomies). Ordered by physicians and coordinated through IVF clinics.
• Previda®-DX (PGT-M) PGT-M test used when a parent carries a specific single-gene variant, chromosomal translocation, or inversion to determine whether embryos carry the same genetic finding before transfer. Uses blood samples from parents to identify specific genetic findings.
• Previda-SR+ (PGT-SR+) PGT-SR+ test for individuals with chromosomal rearrangements including unbalanced translocations, inversions, and balanced translocations, using high-resolution NGS and proprietary algorithms for breakpoint mapping.
• Previda®-Plus Provides triploidy, haploidy, and embryo parentage testing as part of the Previda product family.
• Revela® Portal Online medical portal for case management, secure reporting, consent form management, encrypted result delivery, customer support ticketing, and performance monitoring for IVF clinics and patients, built on HIPAA-compliant infrastructure.

Quantifiable outcome

• PGT-A in the USA avoided nearly 15,000 miscarriages and over 6,500 preterm births in 2023

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators3 records

Recent moves8 records

Expansion highlights5 records

Emerging players

• Genomic Prediction: Genomic Prediction is a niche reproductive genetics lab focused on advanced embryo screening including polygenic risk scoring for IVF. It overlaps with Progenesis's PGT offerings at the high-complexity end of the market and represents an emerging competitor in next-generation embryo assessment.
• Bioarray Genetics: Bioarray Genetics is a specialized reproductive genetics laboratory offering PGT-A and PGT-M services for IVF clinics. As a smaller, specialized lab, it is a comparable emerging player in the PGT category, with similar product scope to Progenesis's Previda family.

Broad incumbents

• Invitae: Invitae is a large clinical genetics platform offering reproductive and carrier screening tests that compete in adjacent indications to PGT. While it does not focus specifically on embryo biopsy PGT, it competes for clinic and patient genetics testing budgets alongside Progenesis.
• Natera: Natera is a publicly traded genetic testing company with a sizable reproductive health franchise (Vistara, Empower, Spectrum) that competes with Progenesis in PGT and non-invasive prenatal screening. It is a much larger incumbent with broader product breadth but overlaps meaningfully with Progenesis's IVF clinic target segment.
• Myriad Genetics: Myriad Genetics is an established molecular diagnostics company with a women's health and reproductive testing portfolio (including Prequel and Foresight carrier screening). It is a broader incumbent competing for the same clinic wallet on reproductive genetics, though with less of an IVF-embedded workflow focus than Progenesis.

Direct peers

• Juno Genetics: Juno Genetics is a UK-based PGT laboratory offering PGT-A, PGT-M, and PGT-SR using NGS for IVF clinics across Europe, the Middle East, and other international markets. It is a comparable specialized PGT lab competitor, particularly relevant given Progenesis's stated sales coverage of European and emerging markets.
• Igenomix (Vitrolife): Igenomix, acquired by Vitrolife, is one of the largest global preimplantation genetic testing labs offering PGT-A, PGT-M, and PGT-SR services to IVF clinics. It is the most directly comparable competitor to Progenesis, serving the same clinic channel with overlapping test menu and global footprint.
• CooperSurgical (Reprogenetics): CooperSurgical's PGT business, including the Reprogenetics lab, provides preimplantation genetic testing for IVF clinics worldwide with a comprehensive PGT-A/PGT-M/PGT-SR menu. It competes head-to-head with Progenesis in the IVF clinic channel and bundles PGT with broader fertility consumables and devices.

Regional players

• Reproductive Genetic Innovations: Reproductive Genetic Innovations is a US-based PGT laboratory serving IVF clinics with PGT-A, PGT-M, and PGT-SR services. It is a US-focused direct competitor of similar scale, comparable to Progenesis in the American clinic channel.

Others

• Sema4 (now part of GeneDx): Sema4, now part of GeneDx, is a clinical genomics platform that historically had a women's health and reproductive screening franchise competing for clinic and patient genetic testing budgets. It is an adjacent/thematic comparable rather than a direct IVF-PGT competitor, illustrating broader diagnostics consolidation dynamics affecting Progenesis's market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ProgenesisInc

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Progenesis